Developer docs
API playgroundTry for free, no card

Search company profiles

Versant Ventures

Full company profile

uuid00000j2

Namestring
Versant Ventures
Legal namestring
Versant Venture Management, LLC
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 that operates a proprietary company-creation platform built around three in-house Discovery Engines: Inception Sciences in San Diego (founded 2011, ~35 drug discovery scientists spanning small molecules, biologics, and nucleic acids), Ridgeline Therapeutics in Basel, Switzerland (operational since 2017), and Frontier in Toronto. The firm raises capital from limited partners via dedicated healthcare-focused venture funds — a $400M vehicle in 2017, $700M and a separate $100M Canadian Fund in 2018, and $950M across three vehicles in 2021 — and reports $5.5B in assets under management with 50+ IPOs and 50+ M&A exits since inception. Versant originates investments by partnering with academic principal investigators through 30+ academic relationships, then launching newco-style biotech companies often with simultaneous build-to-buy pharma partnerships (e.g., BlueRock/Bayer $225M Series A in 2016 and $1B acquisition in 2019, Quanticel/Celgene $45M in 2011 and $485M exit in 2015, Therachon/Pfizer $340M exit in 2019).

The firm's portfolio spans 80+ biotech and medtech companies across gene therapy (Capsida, CRISPR Therapeutics, Passage Bio, Graphite Bio, Audentes), radiopharmaceuticals (RayzeBio, Abdera's ROVEr platform), RNA medicines (Borealis Biosciences with Novartis), cell therapy (BlueRock, Century Therapeutics), targeted protein degradation (Monte Rosa, Lycia's LYTAC platform), bispecific antibodies (Dualitas, Pandion), cardiometabolic/obesity (Helicore, SixPeaks, Pep2Tango, Antag, Akero), and inflammatory/autoimmune diseases (Santa Ana Bio, Jecure, Pandion). Versant earns revenue through management fees on committed and invested fund capital plus carried interest on successful portfolio exits; specific fee economics are not publicly disclosed.

Versant maintains six offices (San Francisco headquarters, San Diego, New York, Toronto, Vancouver, Basel), a 27-person investment team plus 9 operations staff and the ~35 Inception Sciences scientists, and senior leadership drawn heavily from former heads of Roche business development, Novartis M&A, Eli Lilly drug discovery, and AbbVie CSO roles — credentials used to source deals and negotiate build-to-buy structures with global pharma. The legal entity is Versant Venture Management, LLC (US) with a Swiss affiliate, Versant Ventures (Switzerland) GmbH. Recent flagship pharma partnerships include Novartis (Borealis, August 2024, $150M), Biogen (Dayra, November 2024, $70M+), and Merck KGaA (Saturnus Bio, June 2026, $50M upfront plus acquisition option).

Short descriptiontext

Versant Ventures is a healthcare-focused venture capital firm (founded 1999, $5.5B AUM) that operates three in-house Discovery Engines to incubate and invest in biotech newcos alongside global pharma partners via build-to-buy structures, serving academic founders, limited partners, and large pharmaceutical acquirers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, biotech startup investment, drug discovery engines, pharma build-to-buy partnerships, company creation financing
Product category
Healthcare Venture Capital
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture capital fund management fees and carried interest
TypeManaged Services
Description

Versant generates revenue as a venture capital firm managing $5.5 billion across multiple healthcare/biotech-focused funds. Revenue derives from periodic management fees on committed and invested capital in its funds (including Versant's Sixth Healthcare Fund, Canadian Fund, and successor vehicles totaling $950M raised in April 2021 and $700M in 2018) and from carried interest on successful portfolio exits including 50+ IPOs and M&A transactions.

versantventures.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Pricing details1 tier
1Fund economics not publicly disclosed; investments made via closed-end venture funds.
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing/fund terms not publicly disclosed. The Terms of Use note the Site does not constitute an offer to sell or solicitation of any security.

versantventures.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Inception Sciences
Description

Versant's first Discovery Engine, headquartered in San Diego; in-house team of drug discovery scientists forming new biotech companies with academic founders.

versantventures.com
+1 more record
Core offering1 text field

Versant Ventures is a healthcare-focused venture capital firm that manages $5.5B across multiple dedicated funds and originates biotech investments through in-house Discovery Engines (Inception Sciences in San Diego, Ridgeline Therapeutics in Basel, and Frontier in Toronto) that partner with pioneering academics to launch new portfolio companies. The firm then leads Series A/B/C financings into these companies and supplements them with co-investments from global pharma partners via build-to-buy structures providing upfront payments, equity, milestones, and acquisition options.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 50+ IPOs and M&A exits since 1999
+3 more records
Product overview1 text field

Versant Ventures is a healthcare-focused venture capital firm with $5.5B under management that operates a platform-plus-portfolio architecture rather than a single unified software product. Its core operational "product" is its Discovery Engines — in-house scientific infrastructure comprising Inception Sciences in San Diego (founded 2011, ~35 drug discovery scientists covering small molecules, biologics, and nucleic acids) and Ridgeline Therapeutics in Basel, Switzerland (operational since 2017, based in Basel Technology Park) — which serve as the engine for company creation across more than 30 academic partnerships. Built atop this platform is an investment portfolio of 80+ biotech and medtech companies spanning gene therapy (Capsida Biotherapeutics, CRISPR Therapeutics, Passage Bio, Graphite Bio, Audentes Therapeutics), radiopharmaceuticals (RayzeBio, Abdera Therapeutics), RNA medicines (Borealis Biosciences, Lycia Therapeutics with LYTAC degraders), cell therapy (BlueRock Therapeutics, Century Therapeutics), targeted protein degradation (Monte Rosa Therapeutics, Lycia), small molecule oncology (Black Diamond Therapeutics, Nexo Therapeutics, Nested Therapeutics), bispecific antibodies (Dualitas Therapeutics, Pandion Therapeutics), cardiometabolic/obesity (Helicore Therapeutics, SixPeaks Bio, Pep2Tango Therapeutics, Antag Therapeutics, Akero Therapeutics), inflammatory/autoimmune diseases (Santa Ana Bio, Adaxion Therapeutics, Jecure Therapeutics), nephrology (Chinook Therapeutics, Borealis Biosciences), and AI-enabled antibody discovery (Fable Therapeutics). Supporting the limited-partner relationship is an external LP Access portal hosted by Sungard DX.

Product and service4 records
1Inception Sciences Discovery Engine
CategoryInternal Discovery Engine
Description

Inception, Versant's first Discovery Engine, headquartered in San Diego, translates new opportunities from academics into biotechnology company launches. The in-house team of about 35 drug discovery scientists covers small molecules, biologics, and nucleic acids and partners with pioneering academics to launch new biotech companies.

2Ridgeline Therapeutics Discovery Engine
CategoryInternal Discovery Engine
Description

Ridgeline, Versant's European Discovery Engine based in Basel, Switzerland, deploys resources to launch companies derived from European academic institute discoveries. It operates laboratory facilities in Basel Technology Park and employs R&D veterans.

3Versant Ventures Portfolio (Biotech and Medtech Companies)
CategoryInvestment Portfolio
Description

Versant's portfolio comprises 80+ biotech and medtech companies it has created, launched, or invested in across therapeutics (gene therapy, radiopharmaceuticals, RNA medicines, cell therapy, antibody discovery, immunotherapy) and medical devices/diagnostics. Notable current and exited portfolio companies include CRISPR Therapeutics (CRSP), BlueRock Therapeutics, RayzeBio, Lycia Therapeutics, Vividion Therapeutics, Capsida Biotherapeutics, Chinook Therapeutics, Repare Therapeutics, Akero Therapeutics, Black Diamond Therapeutics, Monte Rosa Therapeutics, Century Therapeutics, Passage Bio, and others.

4Versant Ventures LP Access Portal
CategoryInvestor Portal
Description

External limited partner (LP) access portal hosted at https://services.sungarddx.com via Sungard DX, providing LP-facing content and access for limited partners in Versant's venture funds.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Merck KGaA announced a strategic research-stage collaboration with Saturnus Bio, a biotech founded by Versant Ventures, to develop treatments for rare genetic cardiomyopathies using targeted gene modulation. Deal includes $50 million upfront, minority equity stake, and preclinical milestones, with Merck holding exclusive acquisition option plus earnouts.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-21
Description

Versant launched Dayra Therapeutics with $70 million in funding, including a $50 million collaboration with Biogen. Biogen will lead clinical development and commercialization of oral macrocyclic peptides for immunological targets, with options to acquire specific programs.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-08-22
Description

In August 2024, Versant and Novartis launched Borealis Biosciences with $150 million in funding. Borealis is a next-generation RNA medicines company focused on kidney disease.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-04
Description

Versant portfolio company Belharra Therapeutics announced a broad collaboration with Genentech to discover and develop novel medicines across multiple therapeutic areas. Genentech has also previously acquired Versant portfolio companies Jecure Therapeutics and Inception 5, and acquired Enterprise Therapeutics in 2020.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-07-27
Description

Versant Ventures collaborated with AbCellera to accelerate drug development for its portfolio of biotech companies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-08-25
Description

Eli Lilly and Versant portfolio company Lycia Therapeutics entered into a strategic collaboration to discover and develop novel Lysosomal Targeting Chimera (LYTAC) degraders.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-06-15
Description

CRISPR Therapeutics and Versant portfolio company Capsida Biotherapeutics announced a strategic collaboration to develop gene-edited therapies for Amyotrophic Lateral Sclerosis and Friedreich's Ataxia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

Pfizer acquired clinical-stage Versant portfolio company Therachon in May 2019 for $340 million up front.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-03-05
Description

Vividion Therapeutics (Versant portfolio company) announced a strategic research collaboration with Celgene Corporation in March 2018 to discover therapies against transformative, first-in-class targets. Versant later announced the acquisition of Vividion Therapeutics in August 2021.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2016-12-01
Description

In December 2016, Bayer and Versant joined forces to launch stem cell therapy company BlueRock Therapeutics with a USD 225 million Series A financing. BlueRock was subsequently acquired by Bayer for up to $1 billion in August 2019, validating Versant's company-creation partnership model.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-12-01
Description

Johnson & Johnson acquired Versant portfolio company Novira Therapeutics in December 2015 (now part of Janssen). J&J Innovation – JJDC also led Bright Peak Therapeutics' $90 million Series C round in 2024, with additional participation from Versant.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2011-11-01
Description

Quanticel, Celgene and Versant formed a scientific collaboration in November 2011 to discover first-in-class cancer drugs. Celgene committed $45 million to Quanticel and received a 40-month technology license, equity, and time-based acquisition options. Celgene acquired Quanticel in April 2015 for $100M upfront plus up to $385M in contingent payments. Celgene also co-invested in Northern Biologics' build-to-buy agreement.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

VenBio is a biotech-focused venture firm that invests in late-preclinical through commercial-stage therapeutic companies, with a similarly concentrated healthcare mandate. It is comparable to Versant in therapeutic-area focus and stage range, though typically operating without the in-house Discovery Engine infrastructure.

TypeDirect peer
Description

MPM Capital is a dedicated healthcare venture firm that both invests in and co-creates biotech companies, with co-founding activity alongside Versant (e.g., CODA Biotherapeutics). It is a directly comparable peer in company-creation and co-investment activity.

TypeDirect peer
Description

Flagship Pioneering is a venture creation firm that originates and builds biotech platforms (e.g., Moderna) using in-house scientific teams — directly analogous to Versant's Discovery Engine model in approach, scale and fund structure.

TypeBroad incumbent
Description

NEA is a much broader multi-sector VC firm but maintains a sizable dedicated healthcare practice that has co-invested with Versant (e.g., Oyster Point Pharma). Its healthcare investing activities and ability to lead large biotech rounds make it a relevant broad incumbent peer.

TypeDirect peer
Description

Atlas Venture is a biotech-focused early-stage venture firm that builds companies from scratch with academic founders — directly mirroring Versant's Discovery Engine model. Its fund size, therapeutic-area breadth (oncology, immunology, rare disease) and company-creation approach make it a strong direct peer.

TypeDirect peer
Description

ARCH is one of the largest and most established U.S. healthcare/biotech-focused venture capital firms, with a similar company-creation orientation, large dedicated funds, deep pharma partnerships, and a long track record of IPOs and M&A exits. It is the closest direct comparable to Versant in scale and strategy.

TypeDirect peer
Description

OrbiMed is a dedicated healthcare investment firm spanning venture, growth and public equities with multi-billion AUM. Like Versant, it focuses exclusively on healthcare and has a large, established LP base, making it a closely comparable peer in fund structure and sector focus.

TypeDirect peer
Description

5AM Ventures is a dedicated life-sciences venture firm investing across biotech platforms and therapeutic areas, with a comparable fund size and stage focus to Versant. Both firms translate early academic science into portfolio companies with strong pharma-partnered exit profiles.

TypeDirect peer
Description

Frazier is a longstanding healthcare-dedicated venture and growth firm with multiple fund vehicles. Its sector focus, fund-raise cadence and stage range (Series A through growth) closely overlap with Versant's, making it a relevant direct peer.

TypeDirect peer
Description

Third Rock is a biotech venture firm that builds companies from inception with in-house scientific and operational teams — analogous to Versant's Discovery Engine approach. It is one of the most comparable company-creation venture firms in healthcare.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles44 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment401 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Versant Ventures

Healthcare Venture Capitalversantventures.com

Versant Ventures is a healthcare-focused venture capital firm (founded 1999, $5.5B AUM) that operates three in-house Discovery Engines to incubate and invest in biotech newcos alongside global pharma partners via build-to-buy structures, serving academic founders, limited partners, and large pharmaceutical acquirers.

What Versant Ventures does

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 that operates a proprietary company-creation platform built around three in-house Discovery Engines: Inception Sciences in San Diego (founded 2011, ~35 drug discovery scientists spanning small molecules, biologics, and nucleic acids), Ridgeline Therapeutics in Basel, Switzerland (operational since 2017), and Frontier in Toronto. The firm raises capital from limited partners via dedicated healthcare-focused venture funds — a $400M vehicle in 2017, $700M and a separate $100M Canadian Fund in 2018, and $950M across three vehicles in 2021 — and reports $5.5B in assets under management with 50+ IPOs and 50+ M&A exits since inception. Versant originates investments by partnering with academic principal investigators through 30+ academic relationships, then launching newco-style biotech companies often with simultaneous build-to-buy pharma partnerships (e.g., BlueRock/Bayer $225M Series A in 2016 and $1B acquisition in 2019, Quanticel/Celgene $45M in 2011 and $485M exit in 2015, Therachon/Pfizer $340M exit in 2019).

The firm's portfolio spans 80+ biotech and medtech companies across gene therapy (Capsida, CRISPR Therapeutics, Passage Bio, Graphite Bio, Audentes), radiopharmaceuticals (RayzeBio, Abdera's ROVEr platform), RNA medicines (Borealis Biosciences with Novartis), cell therapy (BlueRock, Century Therapeutics), targeted protein degradation (Monte Rosa, Lycia's LYTAC platform), bispecific antibodies (Dualitas, Pandion), cardiometabolic/obesity (Helicore, SixPeaks, Pep2Tango, Antag, Akero), and inflammatory/autoimmune diseases (Santa Ana Bio, Jecure, Pandion). Versant earns revenue through management fees on committed and invested fund capital plus carried interest on successful portfolio exits; specific fee economics are not publicly disclosed.

Versant maintains six offices (San Francisco headquarters, San Diego, New York, Toronto, Vancouver, Basel), a 27-person investment team plus 9 operations staff and the ~35 Inception Sciences scientists, and senior leadership drawn heavily from former heads of Roche business development, Novartis M&A, Eli Lilly drug discovery, and AbbVie CSO roles — credentials used to source deals and negotiate build-to-buy structures with global pharma. The legal entity is Versant Venture Management, LLC (US) with a Swiss affiliate, Versant Ventures (Switzerland) GmbH. Recent flagship pharma partnerships include Novartis (Borealis, August 2024, $150M), Biogen (Dayra, November 2024, $70M+), and Merck KGaA (Saturnus Bio, June 2026, $50M upfront plus acquisition option).

Versant Ventures firmographics

Firmographics
Name
Versant Ventures
Legal name
Versant Venture Management, LLC
Website
https://versantventures.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Versant Ventures is a healthcare-focused venture capital firm (founded 1999, $5.5B AUM) that operates three in-house Discovery Engines to incubate and invest in biotech newcos alongside global pharma partners via build-to-buy structures, serving academic founders, limited partners, and large pharmaceutical acquirers.
Ownership category
akta.pro rank

Where Versant Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Versant Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Venture capital fund management fees and carried interest: Versant generates revenue as a venture capital firm managing $5.5 billion across multiple healthcare/biotech-focused funds. Revenue derives from periodic management fees on committed and invested capital in its funds (including Versant's Sixth Healthcare Fund, Canadian Fund, and successor vehicles totaling $950M raised in April 2021 and $700M in 2018) and from carried interest on successful portfolio exits including 50+ IPOs and M&A transactions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFund economics not publicly disclosed; investments made via closed-end venture funds.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Versant Ventures product offering

Product offering

Core offering

Versant Ventures is a healthcare-focused venture capital firm that manages $5.5B across multiple dedicated funds and originates biotech investments through in-house Discovery Engines (Inception Sciences in San Diego, Ridgeline Therapeutics in Basel, and Frontier in Toronto) that partner with pioneering academics to launch new portfolio companies. The firm then leads Series A/B/C financings into these companies and supplements them with co-investments from global pharma partners via build-to-buy structures providing upfront payments, equity, milestones, and acquisition options.

Product overview

Versant Ventures is a healthcare-focused venture capital firm with $5.5B under management that operates a platform-plus-portfolio architecture rather than a single unified software product. Its core operational "product" is its Discovery Engines — in-house scientific infrastructure comprising Inception Sciences in San Diego (founded 2011, ~35 drug discovery scientists covering small molecules, biologics, and nucleic acids) and Ridgeline Therapeutics in Basel, Switzerland (operational since 2017, based in Basel Technology Park) — which serve as the engine for company creation across more than 30 academic partnerships. Built atop this platform is an investment portfolio of 80+ biotech and medtech companies spanning gene therapy (Capsida Biotherapeutics, CRISPR Therapeutics, Passage Bio, Graphite Bio, Audentes Therapeutics), radiopharmaceuticals (RayzeBio, Abdera Therapeutics), RNA medicines (Borealis Biosciences, Lycia Therapeutics with LYTAC degraders), cell therapy (BlueRock Therapeutics, Century Therapeutics), targeted protein degradation (Monte Rosa Therapeutics, Lycia), small molecule oncology (Black Diamond Therapeutics, Nexo Therapeutics, Nested Therapeutics), bispecific antibodies (Dualitas Therapeutics, Pandion Therapeutics), cardiometabolic/obesity (Helicore Therapeutics, SixPeaks Bio, Pep2Tango Therapeutics, Antag Therapeutics, Akero Therapeutics), inflammatory/autoimmune diseases (Santa Ana Bio, Adaxion Therapeutics, Jecure Therapeutics), nephrology (Chinook Therapeutics, Borealis Biosciences), and AI-enabled antibody discovery (Fable Therapeutics). Supporting the limited-partner relationship is an external LP Access portal hosted by Sungard DX.

Differentiator

Problem solved

Functional benefit

Brands

  • Inception Sciences: Versant's first Discovery Engine, headquartered in San Diego; in-house team of drug discovery scientists forming new biotech companies with academic founders.
  • Ridgeline Therapeutics

Products and services

  • Inception Sciences Discovery Engine Inception, Versant's first Discovery Engine, headquartered in San Diego, translates new opportunities from academics into biotechnology company launches. The in-house team of about 35 drug discovery scientists covers small molecules, biologics, and nucleic acids and partners with pioneering academics to launch new biotech companies.
  • Ridgeline Therapeutics Discovery Engine Ridgeline, Versant's European Discovery Engine based in Basel, Switzerland, deploys resources to launch companies derived from European academic institute discoveries. It operates laboratory facilities in Basel Technology Park and employs R&D veterans.
  • Versant Ventures Portfolio (Biotech and Medtech Companies) Versant's portfolio comprises 80+ biotech and medtech companies it has created, launched, or invested in across therapeutics (gene therapy, radiopharmaceuticals, RNA medicines, cell therapy, antibody discovery, immunotherapy) and medical devices/diagnostics. Notable current and exited portfolio companies include CRISPR Therapeutics (CRSP), BlueRock Therapeutics, RayzeBio, Lycia Therapeutics, Vividion Therapeutics, Capsida Biotherapeutics, Chinook Therapeutics, Repare Therapeutics, Akero Therapeutics, Black Diamond Therapeutics, Monte Rosa Therapeutics, Century Therapeutics, Passage Bio, and others.
  • Versant Ventures LP Access Portal External limited partner (LP) access portal hosted at https://services.sungarddx.com via Sungard DX, providing LP-facing content and access for limited partners in Versant's venture funds.

Quantifiable outcome

  • 50+ IPOs and M&A exits since 1999
  • +3 more outcomes

Companies that use Versant Ventures

Customer profile

Segments5 records

Ideal customer profiles4 records

Versant Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Versant Ventures partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship and core.

  • Merck KGaAflagshipStrategic or Co-development Partner · 23 June 2026Merck KGaA announced a strategic research-stage collaboration with Saturnus Bio, a biotech founded by Versant Ventures, to develop treatments for rare genetic cardiomyopathies using targeted gene modulation. Deal includes $50 million upfront, minority equity stake, and preclinical milestones, with Merck holding exclusive acquisition option plus earnouts.
  • BiogenflagshipStrategic or Co-development Partner · 21 November 2024Versant launched Dayra Therapeutics with $70 million in funding, including a $50 million collaboration with Biogen. Biogen will lead clinical development and commercialization of oral macrocyclic peptides for immunological targets, with options to acquire specific programs.
  • NovartisflagshipStrategic or Co-development Partner · 22 August 2024In August 2024, Versant and Novartis launched Borealis Biosciences with $150 million in funding. Borealis is a next-generation RNA medicines company focused on kidney disease.
  • Genentech (Roche)flagshipStrategic or Co-development Partner · 4 January 2023Versant portfolio company Belharra Therapeutics announced a broad collaboration with Genentech to discover and develop novel medicines across multiple therapeutic areas. Genentech has also previously acquired Versant portfolio companies Jecure Therapeutics and Inception 5, and acquired Enterprise Therapeutics in 2020.
  • AbCelleracoreTechnology or Integration · 27 July 2022Versant Ventures collaborated with AbCellera to accelerate drug development for its portfolio of biotech companies.
  • Eli LillyflagshipStrategic or Co-development Partner · 25 August 2021Eli Lilly and Versant portfolio company Lycia Therapeutics entered into a strategic collaboration to discover and develop novel Lysosomal Targeting Chimera (LYTAC) degraders.
  • CRISPR TherapeuticsflagshipStrategic or Co-development Partner · 15 June 2021CRISPR Therapeutics and Versant portfolio company Capsida Biotherapeutics announced a strategic collaboration to develop gene-edited therapies for Amyotrophic Lateral Sclerosis and Friedreich's Ataxia.
  • PfizercoreStrategic or Co-development Partner · 1 May 2019Pfizer acquired clinical-stage Versant portfolio company Therachon in May 2019 for $340 million up front.
  • Vividion Therapeutics (later acquired by Bayer)flagshipStrategic or Co-development Partner · 5 March 2018Vividion Therapeutics (Versant portfolio company) announced a strategic research collaboration with Celgene Corporation in March 2018 to discover therapies against transformative, first-in-class targets. Versant later announced the acquisition of Vividion Therapeutics in August 2021.
  • BayerflagshipStrategic or Co-development Partner · 1 December 2016In December 2016, Bayer and Versant joined forces to launch stem cell therapy company BlueRock Therapeutics with a USD 225 million Series A financing. BlueRock was subsequently acquired by Bayer for up to $1 billion in August 2019, validating Versant's company-creation partnership model.
  • Johnson & JohnsoncoreStrategic or Co-development Partner · 1 December 2015Johnson & Johnson acquired Versant portfolio company Novira Therapeutics in December 2015 (now part of Janssen). J&J Innovation – JJDC also led Bright Peak Therapeutics' $90 million Series C round in 2024, with additional participation from Versant.
  • CelgeneflagshipStrategic or Co-development Partner · 1 November 2011Quanticel, Celgene and Versant formed a scientific collaboration in November 2011 to discover first-in-class cancer drugs. Celgene committed $45 million to Quanticel and received a 40-month technology license, equity, and time-based acquisition options. Celgene acquired Quanticel in April 2015 for $100M upfront plus up to $385M in contingent payments. Celgene also co-invested in Northern Biologics' build-to-buy agreement.

Scale indicators12 records

Recent moves11 records

Expansion highlights6 records

Versant Ventures competitors and assessment

Company assessment

Direct peers

  • VenBio Partners: VenBio is a biotech-focused venture firm that invests in late-preclinical through commercial-stage therapeutic companies, with a similarly concentrated healthcare mandate. It is comparable to Versant in therapeutic-area focus and stage range, though typically operating without the in-house Discovery Engine infrastructure.
  • MPM Capital: MPM Capital is a dedicated healthcare venture firm that both invests in and co-creates biotech companies, with co-founding activity alongside Versant (e.g., CODA Biotherapeutics). It is a directly comparable peer in company-creation and co-investment activity.
  • Flagship Pioneering: Flagship Pioneering is a venture creation firm that originates and builds biotech platforms (e.g., Moderna) using in-house scientific teams — directly analogous to Versant's Discovery Engine model in approach, scale and fund structure.
  • Atlas Venture: Atlas Venture is a biotech-focused early-stage venture firm that builds companies from scratch with academic founders — directly mirroring Versant's Discovery Engine model. Its fund size, therapeutic-area breadth (oncology, immunology, rare disease) and company-creation approach make it a strong direct peer.
  • ARCH Venture Partners: ARCH is one of the largest and most established U.S. healthcare/biotech-focused venture capital firms, with a similar company-creation orientation, large dedicated funds, deep pharma partnerships, and a long track record of IPOs and M&A exits. It is the closest direct comparable to Versant in scale and strategy.
  • OrbiMed Advisors: OrbiMed is a dedicated healthcare investment firm spanning venture, growth and public equities with multi-billion AUM. Like Versant, it focuses exclusively on healthcare and has a large, established LP base, making it a closely comparable peer in fund structure and sector focus.
  • 5AM Ventures: 5AM Ventures is a dedicated life-sciences venture firm investing across biotech platforms and therapeutic areas, with a comparable fund size and stage focus to Versant. Both firms translate early academic science into portfolio companies with strong pharma-partnered exit profiles.
  • Frazier Healthcare Partners: Frazier is a longstanding healthcare-dedicated venture and growth firm with multiple fund vehicles. Its sector focus, fund-raise cadence and stage range (Series A through growth) closely overlap with Versant's, making it a relevant direct peer.
  • Third Rock Ventures: Third Rock is a biotech venture firm that builds companies from inception with in-house scientific and operational teams — analogous to Versant's Discovery Engine approach. It is one of the most comparable company-creation venture firms in healthcare.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a much broader multi-sector VC firm but maintains a sizable dedicated healthcare practice that has co-invested with Versant (e.g., Oyster Point Pharma). Its healthcare investing activities and ability to lead large biotech rounds make it a relevant broad incumbent peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Versant Ventures social profiles

Digital presence

Versant Ventures compliance and trust

Trust signal

Compliance3 records

Versant Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Versant Ventures leadership team

Management profile

Number of profiles

Profiles44 records

Versant Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Versant Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Versant Ventures M&A and investment

M&A and investment

M&A

Investments401 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Versant Ventures

What does Versant Ventures do?

Versant Ventures is a healthcare-focused venture capital firm that manages $5.5B across multiple dedicated funds and originates biotech investments through in-house Discovery Engines (Inception Sciences in San Diego, Ridgeline Therapeutics in Basel, and Frontier in Toronto) that partner with pioneering academics to launch new portfolio companies. The firm then leads Series A/B/C financings into these companies and supplements them with co-investments from global pharma partners via build-to-buy structures providing upfront payments, equity, milestones, and acquisition options.

Is Versant Ventures a public or private company?

Versant Ventures is a private company. It is classified as venture growth investor backed and is currently operating.

When was Versant Ventures founded?

Versant Ventures was founded in 1999. It employs 51 to 100 people.

Where is Versant Ventures based?

Versant Ventures is headquartered in San Francisco, United States, in the North America region.

How does Versant Ventures make money?

One revenue line is on record: venture capital fund management fees and carried interest.

Who are Versant Ventures's main competitors?

Direct peers on record are VenBio Partners, MPM Capital, Flagship Pioneering, Atlas Venture, ARCH Venture Partners, OrbiMed Advisors, 5AM Ventures, Frazier Healthcare Partners and Third Rock Ventures. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does Versant Ventures have an API?

No public API is recorded for Versant Ventures.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizSeawolf Therapeutics Emerges With $100M to Advance DNA-Based PlatformSeawolf Therapeutics raised $100 million in seed and Series A funding led by Versant Ventures to advance its DNA-based Trident platform. The company also announced a $1.2 billion research and development deal with Sanofi for bleeding disorders and other indications. The capital will support advancing its lead metabolic disease program.FinSMEsSeawolf Therapeutics Raises $100M Across Seed and Series A FundingSeawolf Therapeutics raised $100M in seed and Series A funding, led by Versant Ventures with co-leaders MPM BioImpact and Novartis Venture Fund. The company will use the funds to advance its LNP-based DNA delivery platform, including its lead metabolic disease program and a collaboration with Sanofi.Startup ResearcherSeawolf Therapeutics Launches With US$100 Million FundingSeawolf Therapeutics emerged from stealth with $100 million in financing, led by Versant Ventures, and announced a multi-target research collaboration with Sanofi. The deal includes up to $1.2 billion in milestone payments plus tiered royalties. The company will use the funds to advance its lead metabolic disease program toward Development Candidate.The Pharma LetterSeawolf Therapeutics debuts with $100 million and Sanofi dealSeawolf Therapeutics emerged from stealth after raising $100 million in seed and Series A financing led by Versant Ventures, with participation from Novartis Venture Fund and others. The company will use its proprietary DNA delivery platform to transform patient outcomes. A Sanofi deal was also announced.Dealroom.coSeawolf exits stealth with $100M for DNA-based therapies | Dealroom NewsSeawolf Therapeutics emerged from stealth with $100 million in Series A funding led by Versant Ventures. The company's TRIDENT platform delivers engineered DNA via lipid nanoparticles, and it disclosed a Sanofi collaboration worth up to $1.2 billion. The round aims to advance its lead metabolic disease program amid cooling venture interest in genetic medicines.Business Wire BlogSeawolf Therapeutics Debuts With $100 Million to Advance DNA-Based TherapeuticsSeawolf Therapeutics emerged from stealth after raising $100 million in Series A financing led by Versant Ventures. The company announced a multi-target partnership with Sanofi for up to $1.2 billion in milestones and royalties. Funds will advance its TRIDENT DNA delivery platform, with a lead metabolic disease program advancing to development candidate.STATVersant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issuesVersant Ventures, Eli Lilly, and other investors announced a $100 million investment in Seawolf Therapeutics, a startup developing non-viral gene delivery. Sanofi also partnered with the company. The approach aims to overcome viral gene therapy limitations like antibody responses and side effects.BioPharma DiveBig-name investors pour $100M into DNA therapeutics developer SeawolfSeawolf Therapeutics emerged from stealth with $100 million in seed and Series A funding led by Versant Ventures. The company disclosed a multi-target partnership with Sanofi for DNA-based therapies targeting bleeding disorders and other indications, with potential milestone payments up to $1.2 billion. Its lead program focuses on metabolic diseases.FinancialContent Business PageSeawolf Therapeutics Debuts With $100 Million to Advance DNA-Based TherapeuticsSeawolf Therapeutics emerged from stealth after raising $100 million in Series A financing led by Versant Ventures. The company also announced a multi-target partnership with Sanofi for undisclosed therapies, with milestones up to $1.2 billion and royalties. Funds will advance its TRIDENT DNA delivery platform, including a lead metabolic disease program.YahooBig-name investors pour $100M into DNA therapeutics developer SeawolfSeawolf Therapeutics emerged from stealth with $100 million in seed and Series A funding from investors including Versant Ventures, MPM BioImpact, and Eli Lilly. The company disclosed a partnership with Sanofi for multi-target DNA therapies, with potential milestone payments up to $1.2 billion. Seawolf's TRIDENT platform uses lipid nanoparticles to deliver DNA, aiming for longer-lasting expression than RNA therapies.